Compare Procter & Gamble Co (PG) vs 10X Genomics Inc (TXG) Price & Performance

Procter & Gamble (PG) trades at $149.15, showing minimal daily movement with a neutral technical stance. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 versus $1.56 expected, and robust profitability metrics like a 50.33% gross margin. Recent developments include a multi-year WNBA partnership and ongoing dividend payments of $1.09 per share, supporting its defensive appeal amid market volatility.

PG offers stability with a 53.85% analyst buy rating and $160.50 consensus target, but premium valuations (P/E 21.65) and modest growth outlook pose near-term risks. Supply chain efficiencies and brand strength underpin resilience, though inflation and competitive pressures require monitoring for sustained shareholder returns.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.